What are the indications, dosing regimen, cardiac monitoring requirements, contraindications, and alternative therapies for trastuzumab in HER2‑positive breast or gastric cancer?

Trastuzumab for HER2-Positive Breast and Gastric Cancer

Indications

Trastuzumab is indicated for HER2-positive breast cancer (early and metastatic) and HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma. 1

HER2-Positive Definition

• Patients must have HER2 overexpression confirmed by IHC 3+ OR HER2 gene amplification by FISH to qualify for trastuzumab therapy 2
• Patients with IHC 0,1+, or FISH-negative tumors have very low response rates and should not receive trastuzumab 2
• For gastric cancer, HER2 positivity is defined as IHC 3+ or IHC 2+ with FISH-positive, with scoring criteria differing from breast cancer due to incomplete membranous staining patterns 3
• HER2 positivity occurs in 22% of gastric/GEJ adenocarcinomas, with highest rates in intestinal-type histology and GEJ location 3

Breast Cancer Indications

• Adjuvant treatment of HER2-positive early breast cancer (including tumors >1 cm, though trials excluded tumors <1 cm) 2
• First-line treatment of HER2-positive metastatic breast cancer with or without chemotherapy 2
• Continuation beyond first progression in metastatic disease when combined with different chemotherapy 2

Gastric Cancer Indications

• First-line treatment of HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma in combination with cisplatin and fluoropyrimidine 3

Dosing Regimens

Standard Every-3-Week Schedule (Preferred)

• Loading dose: 8 mg/kg IV on day 1 1
• Maintenance: 6 mg/kg IV every 21 days 1
• This schedule is pharmacokinetically equivalent to weekly dosing with greater patient convenience 1

Weekly Schedule (Alternative)

• Loading dose: 4 mg/kg IV on day 1 1
• Maintenance: 2 mg/kg IV weekly 1
• Particularly useful when combined with weekly chemotherapy regimens such as weekly paclitaxel 1

Duration of Treatment

• Adjuvant breast cancer: 1 year (52 weeks) total duration, including any neoadjuvant and adjuvant cycles 1, 2
• Metastatic disease: Continue until disease progression or unacceptable toxicity, with evidence supporting continuation beyond first progression 2
• The optimal duration in patients with long-term disease control remains unknown 2

Cardiac Monitoring Requirements

Baseline LVEF assessment is mandatory before initiating trastuzumab, with patients having LVEF <50-55% contraindicated for treatment. 1, 2

Monitoring Schedule

• Assess LVEF at baseline before starting therapy 1
• Re-evaluate LVEF every 3 months throughout treatment 1
• More frequent monitoring may be warranted in high-risk patients 1

Discontinuation Criteria

• Stop trastuzumab if LVEF falls below 50% or institutional safety thresholds 1
• Discontinue immediately if symptomatic heart failure develops 1
• Cardiac dysfunction appears mostly reversible with treatment discontinuation 4

Contraindications and Critical Warnings

Absolute Contraindications

• LVEF <50-55% at baseline 1, 2
• Pre-existing symptomatic heart failure 2
• HER2-negative disease (IHC 0/1+ or FISH-negative) 2

Concurrent Anthracycline Prohibition

• Never administer trastuzumab concurrently with anthracyclines (doxorubicin, epirubicin) due to severe cardiotoxicity risk 1, 2
• Cardiotoxicity rates increase from 2-4% to 27% when trastuzumab is combined with anthracycline/cyclophosphamide 2
• When anthracyclines are used, complete the anthracycline phase first, then start trastuzumab with the subsequent taxane phase 1

Sequencing with Chemotherapy

• Trastuzumab should be administered concurrently with taxane-based chemotherapy for optimal efficacy 1
• Safe combinations include trastuzumab with paclitaxel (with or without carboplatin), docetaxel, vinorelbine, or capecitabine 2

Preferred Treatment Regimens by Setting

First-Line Metastatic Breast Cancer

Pertuzumab + trastuzumab + taxane is the preferred first-line regimen for HER2-positive metastatic breast cancer based on superior overall survival 2

• Pertuzumab/trastuzumab/docetaxel is category 1 (highest evidence) 2
• Pertuzumab/trastuzumab/paclitaxel is category 2A 2
• T-DM1 with or without pertuzumab is an alternative for patients unsuitable for the preferred regimen, though it should not be first-line when pertuzumab/trastuzumab/taxane is feasible 2

Second-Line and Beyond (Metastatic Breast Cancer)

• Continue HER2 blockade after progression on first-line trastuzumab 2
• Options include: trastuzumab with different chemotherapy, T-DM1, lapatinib + capecitabine, or trastuzumab + lapatinib 2
• For patients who progressed on trastuzumab without prior pertuzumab, add pertuzumab to trastuzumab with or without chemotherapy 2

Adjuvant Breast Cancer

• Trastuzumab should be given concurrently with taxane chemotherapy after completing anthracycline-based therapy 2
• Do not give trastuzumab with endocrine therapy alone without chemotherapy (not supported by evidence) 2

Gastric/GEJ Cancer

• Trastuzumab + cisplatin + fluoropyrimidine (capecitabine or 5-FU) is standard first-line therapy for HER2-positive advanced disease 3
• This combination improved median overall survival from 11.1 to 13.8 months (p=0.0046) 3

Alternative Therapies for Trastuzumab-Refractory Disease

After Trastuzumab Failure in Breast Cancer

• T-DM1 (ado-trastuzumab emtansine): Antibody-drug conjugate showing superior progression-free survival (9.6 vs 6.4 months) and overall survival compared to lapatinib + capecitabine 2
• Lapatinib + capecitabine: Increases time to progression from 4.4 to 8.4 months in trastuzumab-refractory disease 2
• Trastuzumab + lapatinib (dual HER2 blockade): Increases progression-free survival from 8.1 to 12 weeks 2
• Pertuzumab + trastuzumab: 24% objective response rate in trastuzumab-refractory patients, with clinical benefit rate of 50% 2

Endocrine Therapy Combinations (ER+/HER2+ Disease)

• Addition of trastuzumab or lapatinib to endocrine therapy prolongs progression-free survival in ER-positive/HER2-positive tumors 2

Gastric Cancer After Trastuzumab

• Novel HER2 antibody-drug conjugates are under investigation for trastuzumab-refractory gastric cancer 5
• Strategies proven effective in breast cancer have largely failed in gastric cancer 5

Common Pitfalls and How to Avoid Them

Dosing Errors

• Do not reduce the 8 mg/kg loading dose based on age alone; use standard dosing unless specific contraindications exist 1
• Do not truncate therapy before completing 1 year in the adjuvant setting, as full duration is required for maximal benefit 1

Cardiac Monitoring Failures

• Do not omit scheduled cardiac monitoring; asymptomatic dysfunction can occur and necessitate dose modification 1
• Do not continue trastuzumab if LVEF drops below 50%, even if asymptomatic 1

Chemotherapy Sequencing Errors

• Never give trastuzumab with anthracyclines concurrently outside clinical trials 1, 2
• Always complete anthracycline therapy before starting trastuzumab 1

HER2 Testing Pitfalls

• Do not treat based on IHC 2+ alone without FISH confirmation 2
• Be aware that false-positive HER2 determinations are common; ensure proper assay validation 2
• For gastric cancer, use gastric-specific HER2 scoring criteria, not breast cancer criteria 3

Treatment Discontinuation Errors

• Do not stop trastuzumab at first progression in metastatic disease; continue HER2 blockade with different chemotherapy or add pertuzumab 2